What is it about?
We evaluated the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected in Ita4. Over half (54.6%) of these isolates were resistant to colistin. The SUL–DUR combination was active against these CRAb isolates with MIC50 and MIC90 values of 0.5 mg/L and 4 mg/L, respectively. Only eleven isolates were resistant to SUL–DUR with MIC values ranging from 8 to 128 mg/L. The SUL–DUR resistant A. baumannii exhibited several antimicrobial resistance genes (ARGs) such as blaOXA-20, blaOXA-58, blaOXA-66, blaADC-25, aac(60)-Ib3 and aac(60)-Ib-cr and mutations in gyrA (S81L) and parC (V104I, D105E). However, in these isolates, mutations Q488K and Y528H were found in PBP3. Different determinants were also identified in these CRAb isolates, including adeABC, adeFGH, adeIJK, abeS, abaQ, and abaR, which encode multidrug efflux pumps associated with resistance to multiple antibacterial agents.
Featured Image
Photo by CDC on Unsplash
Why is it important?
This study provides a "time-zero" on the activity of sulbactam/durlobactam against Acinetobacter in Italy
Read the Original
This page is a summary of: In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy, Antibiotics, August 2022, MDPI AG,
DOI: 10.3390/antibiotics11081136.
You can read the full text:
Contributors
The following have contributed to this page
